Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 2/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574577 | 0.85 | CYP3A4 (0.77) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| SCHEMBL29783018 | 0.85 | CYP3A4 (0.77) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| SCHEMBL595294 | 0.85 | CYP1A2 (0.77) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| SCHEMBL20647003 | 0.84 | SMN1; SMN2 (0.71) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| SCHEMBL3065347 | 0.83 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL11388179 | 0.83 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| SCHEMBL5211666 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL1679765 | 0.83 | CYP3A4 (0.75) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| SCHEMBL11393856 | 0.83 | CYP1A2 (0.77) | CYP1A2CYP3A4CYP2C19LMNAMEN1 | |
| SCHEMBL11385285 | 0.83 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2C19LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009073719-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | CYP1A2 140/4885CYP3A4 10/4885CYP2C19 209/4885 |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | CYP1A2 1995/4885CYP3A4 3308/4885CYP2C19 2645/4885 |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | CYP1A2 1849/4885CYP3A4 3175/4885CYP2C19 2557/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | CYP1A2 1849/4885CYP3A4 3175/4885CYP2C19 2557/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | CYP1A2 1995/4885CYP3A4 3308/4885CYP2C19 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.